Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
We will be comparing the two most commonly used drugs to treat hypertension, atenolol and bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced.
We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study.The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded.
The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period.
At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1 and 2 hours.
Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is < 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.
Studietyp
Inskrivning
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Cambridge, Storbritannien, CB2 2QQ
- Rekrytering
- Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital
-
Kontakt:
- Mrs M Watts
- Telefonnummer: 01223 586865
- E-post: mw363@medschl.cam.ac.uk
-
Kontakt:
- Dr A Stears, MBBS BSc MRCP
- Telefonnummer: 01223 586878
- E-post: as659@medschl.cam.ac.uk
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Volunteers will be aged 18-75 years.
Hypertension- either
- untreated, BP 140-170/90-110
- treated for over 1 month with drugs other than beta blockers or diuretic and BP>140/85
- treated for over 1 month with drugs other than beta blockers or diuretic and BP<140/85 and patient willing to change medication for eight months.
Exclusion criteria:
- Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.
- Any patient who is intolerant of these medications will be excluded from the study.
- Patients with gout, asthma or any other contraindications to the study drugs will be excluded.
- Women of child bearing age not using contraception.
- Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)
- Volunteers not able to give informed consent
- Patients with diabetes
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vad mäter studien?
Primära resultatmått
Resultatmått |
|---|
|
Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?
|
Sekundära resultatmått
Resultatmått |
|---|
|
Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?
|
|
Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Professor MJ Brown, MA MSC MD FRCP, Addenbrookes Hosptal NHS Trust/ University of Cambridge
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- OGTT1
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .